Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-720-9 | CAS number: 29598-76-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute Oral Toxicity: LD50 >2000 mg/kg bw (female Wistar rats)
Acute Dermal Toxicity: LD50 >2000 mg/kg bw (male/female Crl:WI Wistar rats)
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 13 August 2015 to 01 September 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study performed in accordance with OECD, EU, US EPA & Japanese test guidelines in compliance with GLP.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- See Any other information
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- Deviations:
- yes
- Remarks:
- see Any other information
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1100 (Acute Oral Toxicity)
- Deviations:
- yes
- Remarks:
- see Any other information
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF Guidelines (2000), including the most recent revisions.
- Deviations:
- yes
- Remarks:
- see Any other information
- GLP compliance:
- yes
- Test type:
- acute toxic class method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species: Rat, Wistar strain Crl:WI (Han) (outbred, SPF-Quality). Recognized by international guidelines as the recommended test system (e.g. OECD, EC).
Source: Charles River Deutschland, Sulzfeld, Germany.
Number of animals: 6 Females (nulliparous and non-pregnant). Each dose group consisted of 3 animals.
Age and body weight: Young adult animals (approx. 10-11 weeks old) were selected. Body weight variation did not exceed +/- 20% of the sex mean.
Identification: Earmark and tail mark
Health inspection: At least prior to dosing. It was ensured that the animals were healthy and without any abnormality that might affect the study integrity.
Animal husbandry
Conditions
Environmental controls for the animal room are set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 air changes/hour, and a 12-hour light/12-hour dark cycle: the photoperiod is between 07:00 and 19:00 hrs daily. The light/dark cycle may be interrupted for study related activities. Any variations to these conditions will be evaluated and maintained in the raw data.
Accommodation
Group housing of 3 animals per cage in labeled Makrolon cages (MIV type; height 18 cm.) containing sterilized sawdust as bedding material (Lignocel S 8-15, JRS - J.Rettenmaier & Söhne GmbH + CO. KG, Rosenberg, Germany) and paper as cage-enrichment (Enviro-dri, Wm. Lillico & Son (Wonham Mill Ltd), Surrey, United Kingdom).
Acclimatization period was at least 5 days before start of treatment under laboratory conditions.
Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany).
Water: Free access to tap water.
Diet, water, bedding and cage enrichment evaluation for contaminants and/or nutrients was performed according to facility standard procedures. There were no findings that could interfere with the study. - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- Vehicle: Corn oil (Fagron Capelle a/d IJssel, The Netherlands) (specific gravity 0.92)
Rationale: The vehicle was selected based on trial preparations performed at WIL Research Europe and on test substance data supplied by the Sponsor.
There was no information available regarding the solubility or stability in vehicle.
Preparation: The preparations (w/w) were dosed within 4 hours after adding the vehicle to the test substance. Homogeneity was assessed by visual inspection of the solutions and the formulations were stirred during dosing, which ensures homogeneity sufficient for these kinds of studies.
Adjustment was made for specific gravity of the vehicle. No correction was made for purity of the test substance.
The toxicity of the test substance was assessed by stepwise treatment of groups of 3 females. The first group was treated at a dose level of 2000 mg/kg. The absence or presence of mortality of animals dosed at one step determined the next step, based on the test procedure defined in the guidelines.
The onset, duration and severity of the signs of toxicity were taken into account for determination of the time interval between the dose groups. - Doses:
- 2000 mg/kg (10 mL/kg) body weight.
- No. of animals per sex per dose:
- 3 animals
- Control animals:
- no
- Details on study design:
- Treatment
Method: Oral gavage, using plastic feeding tubes. The test item preparations were stirred on a magnetic stirrer during dosing.
Fasting: Animals were deprived of food overnight prior to dosing and until 3-4 hours after administration of the test substance. Water was available ad libitum.
Frequency: Single dosage on Day 1.
Dose level (volume): 2000 mg/kg (10 mL/kg) body weight.
Observations
Mortality/Viability: Twice daily.
Body weights: Days 1 (pre-administration), 8 and 15.
Clinical signs: At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15. The signs were graded according to fixed scales and the time of onset, degree and duration were recorded:
Maximum grade 4: grading slight (1) to very severe (4)
Maximum grade 3: grading slight (1) to severe (3)
Maximum grade 1: presence is scored (1).
Necropsy: At the end of the observation period, all animals were sacrificed by oxygen/carbon dioxide procedure and subjected to necropsy.
Descriptions of all internal macroscopic abnormalities were recorded. - Statistics:
- No statistical analysis was performed (The method used is not intended to allow the calculation of a precise LD50 value).
- Preliminary study:
- Preiminary study not undertaken.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- No mortality occurred.
- Clinical signs:
- Hunched posture (grade 1) and/or piloerection (grade 1) were noted for four females on Day 1 and/or 2.
Alopecia (grade 1), noted for one animal, from Day 6 onwards, is commonly seen in group housed rats and therefore no toxicological significance was attached to this finding. - Body weight:
- The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain.
- Gross pathology:
- No abnormalities were found at macroscopic post mortem examination of the animals.
- Other findings:
- No further findings specified in the study report.
- Interpretation of results:
- not classified
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The oral LD50 value of 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Wistar rats was established to exceed 2000 mg/kg body weight.
- Executive summary:
Assessment of acute oral toxicity with 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in the rat (Acute Toxic Class Method).
The study was carried out based on the guidelines described in:
OECD No.423 (2001) "Acute Oral Toxicity, Acute Toxic Class Method"
Commission Regulation (EC) No 440/2008, B1 tris: "Acute Oral Toxicity, Acute Toxic Class Method"
EPA, OPPTS 870.1100 (2002), "Acute Oral Toxicity"
JMAFF Guidelines (2000), including the most recent revisions.
2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was administered by oral gavage to two subsequent groups of three female Wistar rats at 2000 mg/kg body weight. Animals were subjected to daily observations and weekly determination of body weight.
Macroscopic examination was performed after terminal sacrifice (Day 15).
No mortality occurred.
Hunched posture (grade 1) and/or piloerection (grade 1) were noted for four females on Day 1 and/or 2.
The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain.
No abnormalities were found at macroscopic post mortem examination of the animals.
The oral LD50 value of 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Wistar rats was established to exceed 2000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to exceed 5000 mg/kg body weight.
Based on these results, 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (including all amendments).
Reference
MORTALITY DATA
TEST DAY |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
HOURS AFTER TREATMENT |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FEMALES 2000 MG/KG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
FEMALES 2000 MG/KG |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
CLINICAL SIGNS
TEST DAY |
1 |
1 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
15 |
|
HOURS AFTER TREATMENT |
0 |
2 |
4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MAX GRADE |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
FEMALES 2000 MG/KG |
||||||||||||||||||
ANIMAL 1 No clinical signs noted |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
ANIMAL 2 Posture -Hunched posture Skin / fur -Alopecia |
(1)
(3) |
1
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
-
1 |
ANIMAL 3 No clinical signs noted |
|
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
FEMALES 2000 MG/KG |
||||||||||||||||||
ANIMAL 4 Posture -Hunched posture Skin / fur -Piloerection |
(1)
(1) |
1
- |
1
1 |
1
1 |
1
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
ANIMAL 5 Posture -Hunched Posture Skin / fur -Piloerection |
(1)
(1) |
1
- |
1
1 |
1
1 |
1
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
ANIMAL 6 Posture -Hunched Posture Skin / fur -Piloerection |
(1)
(1) |
1
- |
1
1 |
1
1 |
1
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
-
- |
- = Sign not observed
BODY WEIGHTS (GRAM)
SEX/DOSE LEVEL |
ANIMAL |
DAY 1 |
DAY 8 |
DAY 15 |
FEMALES 2000 MG/KG |
1 2 3
MEAN ST. DEV. N |
196 189 191
192 4 3 |
215 214 229
219 8 3 |
218 218 242
226 14 3 |
FEMALES 2000 MG/KG |
4 5 6
MEAN ST. DEV. N |
177 156 183
172 14 3 |
201 173 208
194 19 3 |
215 187 218
207 17 3 |
MACROSCOPIC FINDINGS
ANIMAL ORGAN |
FINDING |
DAY OF DEATH |
FEMALES 2000 MG/KG |
||
1 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
2 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
3 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
FEMALES 2000 MG/KG |
||
4 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
5 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
6 |
No findings noted |
Scheduled necropsy Day 15 after treatment |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- K1
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 April 2017 to 25 April 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- OECD GUIDELINES FOR TESTING OF CHEMICALS (No.: 402, 24th Feb. 1987)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Version / remarks:
- Commission Regulation (EC) No 440/2008, B.3 (L 142, 30 May 2008)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.1200 (Acute Dermal Toxicity)
- Version / remarks:
- OPPTS 870.1200 (EPA 712-C-98-192, August 1998)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- standard acute method
- Limit test:
- yes
- Specific details on test material used for the study:
- No further details specified.
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl:WI Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld, Germany
Hygienic level at arrival: SPF
Hygienic level during the study: Standard housing conditions
Justification of strain: The Wistar rat is one of the standard rodent species used in acute toxicity studies.
Number of animals: 5 animals/sex
Sex: Male and female, female rats were nulliparous and non-pregnant.
Age of animals at dosing: Young adult rats
Body weight range at dosing: Between 218 g and 254 g
Acclimation time: 5 days
Husbandry
Animal health: Only healthy animals were used for the study.
The staff Veterinarian certified the health status.
Room-Box: 242/7
Housing: Individual caging
Cage type: Type II. polypropylene/polycarbonate
Bedding: Lignocel 3/4-S Hygienic Animal Bedding was available to animals during the study. Copy of the Certificate of Analysis is retained in the archive at CiToxLAB Hungary Ltd.
Nesting: Nest building material Arbocel Crinklets natural was available to animals during the study. Copy of the Certificate of Analysis is retained in the archive at CiToxLAB Hungary Ltd.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.4–24.7°C
Relative humidity: 30–58%
Ventilation: 15-20 air exchanges/hour
Enrichment: Rodents were housed with deep wood sawdust bedding to allow digging and other normal rodent activities.
Temperature and relative humidity were recorded twice daily during the study.
Food and Water Supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice – breeding and maintenance", ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study and the water was considered fit for human consumption.
The batch of feed employed in the study was as follow:
• 285 17890, expiry date: 31 August 2017
The supplier provided an analytical certificate for the batch used. A copy of the certificate will be archived with the raw data.
Water quality control analysis is performed once every three months and microbiological assessment is performed monthly by Veszprém County Institute of State Public Health and Medical Officer Service. The quality control results are retained in the archives at CiToxLAB Hungary Ltd.
Animal Identification
Animals were individually identified using numbers written on the tail with an indelible pen. The numbers were given on the basis of CiToxLAB Hungary Ltd.'s Master File for each animal allocated to the treatment groups. The cages were identified by cards containing information about study code, sex, dose group, cage number and individual animal number. - Type of coverage:
- semiocclusive
- Vehicle:
- water
- Details on dermal exposure:
- Formulation
The test item was powdered and administered as a single dose. Sufficient water was used to dampen the test material to ensure good contact with the skin.
Procedure
The back of each animal was shaved (approximately 10% area of the total body surface) approximately 24 hours prior to treatment. The test item was applied to the shaved skin as a single dose and remained in contact with the skin for the 24-hour exposure period. Sterile gauze pads were placed on the skin of rats to cover the test item. These gauze pads were kept in contact with the skin using a patch with adhesive hypoallergenic plaster. The entire trunk of the animal was then wrapped with semi occlusive plastic wrap for 24 hours.
At the end of the exposure period, the treated area of skin with the test item was washed with water at body temperature. - Duration of exposure:
- A single dermal application was made.
- Doses:
- The test item was not expected to be lethal at 2000 mg/kg bw. A limit test was therefore performed.
- No. of animals per sex per dose:
- 10 (5 males/5 females)
- Control animals:
- not required
- Details on study design:
- OBSERVATIONS
Clinical Observations
Clinical observations were performed on the day of treatment at 1 and 5 hours after application of the test item and once each day for 14 days thereafter.
Observations included the skin and fur, eyes and mucous membranes, the respiratory, circulatory, autonomic and central nervous system, somatomotor activity and behaviour pattern. Particular attention was directed to observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Skin Irritation
Adverse skin reactions at the site of application were recorded daily following the removal of the dressing.
Measurement of Body Weight
The body weights were recorded on Day 0 (before test item administration) and on Days 7 and 14 just before necropsy.
NECROPSY
Macroscopic examination was performed on all animals. All animals were anaesthetised with pentobarbital sodium and exsanguinated.
Following confirmation of death, after examination of the external appearance, the cranial, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed. All macroscopic changes were recorded. - Statistics:
- The method used was not intended to allow the calculation of a precise LD50 value.
Body weight and body weight gain are summarised in tabular form. Clinical signs and necropsy findings are described and summarised in tabular form. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- The test item did not cause mortality at the dose level of 2000 mg/kg bw.
- Clinical signs:
- There were no systemic clinical signs noted in any animal throughout the study.
- Body weight:
- There were no treatment related effects on body weight or body weight gain during the observation period.
- Gross pathology:
- There was no evidence of any gross observations at a dose level of 2000 mg/kg bw.
- Other findings:
- Local Dermal Signs
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period. - Interpretation of results:
- GHS criteria not met
- Conclusions:
- The acute dermal median lethal dose (LD50) of the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats.
- Executive summary:
An acute dermal toxicity study was performed with the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Crl:WI Wistar rats, in compliance with OECDGuideline No.: 402.
A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex). The test item was powdered and applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 1 and 5 hours after dosing and daily for 14 days thereafter. Body weight was measured prior to dosing on Day 0 and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at the end of the 2-week observation period (Day 14).
The results of the study were summarised as follows:
Mortality
Test item did not cause mortality at the dose level of 2000 mg/kg bw.
Systemic clinical signs
There were no systemic clinical signs noted in any animal throughout the study.
Local dermal signs
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
Body weight and body weight gain
There were no treatment related effects on body weight or body weight gain during the observation period.
Necropsy
There was no evidence of any gross observations at a dose level of 2000 mg/kg bw.
Conclusions
The acute dermal median lethal dose (LD50) of the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats.
According to the GHS criteria, 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] can be ranked as "Category 5" or "Unclassified" for acute dermal exposure.
Reference
Clinical Observations
DOSE LEVEL: 2000 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Observations |
Observations days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
1 |
7960 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
2 |
7961 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
3 |
7962 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
4 |
7963 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
5 |
7964 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
DOSE LEVEL: 2000 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Observations |
Observations days |
Frequency |
|||||||||||||||
0 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
|||||
1h |
5h |
||||||||||||||||||
6 |
7975 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
7 |
7976 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
8 |
7977 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
9 |
7978 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
10 |
7979 |
Symptom Free |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
+ |
16/16 |
Remarks: + = present
h = hour Treatment day = Day 0
Frequency of observation = number of occurrence of observation / total number of observations
Body Weight Data
DOSE LEVEL: 200 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
1 |
7960 |
220 |
252 |
290 |
32 |
38 |
70 |
2 |
7961 |
244 |
300 |
353 |
56 |
53 |
109 |
3 |
7962 |
251 |
300 |
350 |
49 |
50 |
99 |
4 |
7963 |
230 |
279 |
325 |
49 |
46 |
95 |
5 |
7964 |
224 |
263 |
296 |
39 |
33 |
72 |
Mean: |
233.8 |
278.8 |
322.8 |
45.0 |
44.0 |
89.0 |
|
Standard deviation: |
13.2 |
21.6 |
29.4 |
9.5 |
8.3 |
17.2 |
DOSE LEVEL: 200 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Body weight (g) Days |
Body Weight Gain (g) |
||||
0 |
7 |
14 |
0-7 |
7-14 |
0-14 |
||
6 |
7975 |
233 |
235 |
247 |
2 |
12 |
14 |
7 |
7976 |
222 |
227 |
234 |
5 |
7 |
12 |
8 |
7977 |
218 |
235 |
252 |
17 |
17 |
34 |
9 |
7978 |
232 |
233 |
239 |
1 |
6 |
7 |
10 |
7979 |
254 |
259 |
302 |
5 |
43 |
48 |
Mean: |
231.8 |
237.8 |
254.8 |
6.0 |
17.0 |
23.0 |
|
Standard deviation: |
14.0 |
12.3 |
27.3 |
6.4 |
15.2 |
17.3 |
Macroscopic Findings
DOSE LEVEL: 2000 mg/kg bw SEX: MALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ / Tissue |
1 |
7960 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
2 |
7961 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
3 |
7962 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
4 |
7963 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
5 |
7964 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
DOSE LEVEL: 2000 mg/kg bw SEX: FEMALE
Cage No. |
Animal No. |
Necropsy Date/ Necropsy Day |
External Observations |
Internal Observations |
Organ / Tissue |
6 |
7975 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
7 |
7976 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
8 |
7977 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
9 |
7978 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
10 |
7979 |
25 April 2017 Day 14 |
No external observations |
No internal observations |
Not applicable |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- K1
Additional information
Acute Oral Toxicity
2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was administered by oral gavage to two subsequent groups of three female Wistar rats at 2000 mg/kg body weight. Animals were subjected to daily observations and weekly determination of body weight.
Macroscopic examination was performed after terminal sacrifice (Day 15).
No mortality occurred.
Hunched posture (grade 1) and/or piloerection (grade 1) were noted for four females on Day 1 and/or 2.
The body weight gain shown by the animals over the study period was considered to be similar to that expected for normal untreated animals of the same age and strain.
No abnormalities were found at macroscopic post mortem examination of the animals.
The oral LD50 value of 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Wistar rats was established to exceed 5000 mg/kg body weight.
According to the OECD 423 test guideline, the LD50 cut-off value was considered to exceed 5000 mg/kg body weight.
Acute Dermal Toxicity
An acute dermal toxicity study was performed with the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] in Crl:WI Wistar rats.
A limit test was carried out at 2000 mg/kg body weight (bw) in both sexes (5 rats/sex). The test item was powdered and applied as a single dermal 24-hour exposure followed by a 14-day observation period.
Clinical observations were performed on all animals at 1 and 5 hours after dosing and daily for 14 days thereafter. Body weight was measured prior to dosing on Day 0 and on Days 7 and 14 (before necropsy). Gross macroscopic examination was performed on all animals at the end of the 2-week observation period (Day 14).
The results of the study were summarised as follows:
Test item did not cause mortality at the dose level of 2000 mg/kg bw.
There were no systemic clinical signs noted in any animal throughout the study.
No adverse local dermal signs were observed after treatment with the test item or during the 14 days observation period.
There were no treatment related effects on body weight or body weight gain during the observation period.
There was no evidence of any gross observations at a dose level of 2000 mg/kg bw.
The acute dermal median lethal dose (LD50) of the test item 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] was found to be greater than 2000 mg/kg body weight in male and female Crl:WI rats.
Justification for selection of acute toxicity – oral endpoint
Endpoint conclusion derived in GLP accredited laboratory study in accordance with OECD Guideline 423, EU Method B.1 tris and US EPA Procedure 870.1100
Justification for selection of acute toxicity – oral endpoint
Endpoint conclusion derived in GLP accredited laboratory study in accordance with OECD Guideline 402, EU Method B.3 and US EPA Procedure 870.1200
Justification for classification or non-classification
Acute Oral Toxicity
2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] does not have to be classified and has no obligatory labelling requirement for acute oral toxicity according to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) of the United Nations (2011) (including all amendments) and Regulation (EC) No 1272/2008 on classification, labelling and packaging of substances and mixtures (including all amendments).
Acute Dermal Toxicity
According to the GHS criteria, 2,2-Bis[[3-(dodecylthio)-1-oxopropoxy]methyl]propane-1,3-diyl bis[3-(dodecylthio)propionate] can be ranked as "Category 5" or "Unclassified" for acute dermal exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.